The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


AREXVY



GlaxoSmithKline BiologicalsEU/1/23/1740/001-002

Main Information

Trade NameAREXVY
Active SubstancesRecombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E
Dosage FormPowder and suspension for suspension for injection
Licence HolderGlaxoSmithKline Biologicals
Licence NumberEU/1/23/1740/001-002

Group Information

ATC CodeJ07BX05 respiratory syncytial virus vaccines

Status

License statusAuthorised
Licence Issued06/06/2023
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back